Pharmafile Logo

Vivid Medical Communications Supports the 10th Anniversary of Rare Diseases Day 2018

Vivid Medical Communications – a newly created rare diseases specialist agency and part of the successful Lucid Group of companies – is a proud supporter of Rare Diseases Day 2018.

- PMLiVE

Collectively, rare diseases comprise 6,000 conditions that affect over 600 million people around the world. Rare Diseases Day aims to raise awareness of the impact of rare diseases on patients and their families to both health policy makers and the general public. Organised by Rare Diseases Europe (EURODIS), and with the tagline Show you’re rare, show you care, Rare Diseases Day has been held on the last day in February since 2008, and will be marked this year by 301 events in 66 countries. 

Rare Diseases Day is an encouraging time for patients with rare diseases and for Vivid, according to Alison Cantle, Vivid’s newly appointed MD. With interest and funding support from both Governmental Health Departments and big pharma, intensive research efforts are beginning to show real promise. Several major pharmaceutical companies now have a number of promising drug candidates in their commercialisation pipelines, she added.

Vivid is the only healthcare agency set up as a dedicated rare diseases medical communications practice, and offers the full spectrum of medical communications services tailored specifically to the needs of the rare diseases sector. Its bespoke services include a dedicated online consensus platform to support the delivery of clinical recommendations on disease management, specialist medical writing services from a team experienced in rare diseases, clinical investigator and opinion leader events, and patient advocacy development.

For further information please contact Alison@vividmedcomms.com
You can also find out more on the website http://www.lucid-group.co.uk/vivid/

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD